Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials

S Bangalore, R Fakheri, B Toklu, G Ogedegbe… - Mayo Clinic …, 2016 - Elsevier
Objectives To compare the efficacy and safety of angiotensin-converting enzyme inhibitors
(ACEis) and angiotensin receptor blockers (ARBs) in patients without heart failure. Patients …
被引用次数：114 相关文章

Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized …

S Bangalore, R Fakheri, B Toklu, G Ogedegbe… - Mayo Clinic …, 2016 - folia.unifr.ch
RESULTS Our search yielded 106 randomized trials that enrolled 254,301 patients.
Compared with placebo, ACEis but not ARBs reduced the outcomes of all-cause mortality …

Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized …

S Bangalore, R Fakheri, B Toklu… - Mayo Clinic …, 2016 - pubmed.ncbi.nlm.nih.gov
Objectives To compare the efficacy and safety of angiotensin-converting enzyme inhibitors
(ACEis) and angiotensin receptor blockers (ARBs) in patients without heart failure. Patients …

Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized …

S Bangalore, R Fakheri, B Toklu, G Ogedegbe… - Mayo Clinic …, 2016 - infona.pl
To compare the efficacy and safety of angiotensin-converting enzyme inhibitors (ACEis) and
angiotensin receptor blockers (ARBs) in patients without heart failure. Meta-analysis of …

Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized …

S Bangalore, R Fakheri, B Toklu… - Mayo Clinic …, 2016 - europepmc.org
Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without
Heart Failure? Insights From 254,301 Patients From Randomized Trials. - Abstract - Europe …

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials

S Bangalore, R Fakheri, B Toklu, G Ogedegbe… - Mayo Clinic …, 2016 - go.gale.com
Objectives: To compare the efficacy and safety of angiotensin-converting enzyme inhibitors
(ACEis) and angiotensin receptor blockers (ARBs) in patients without heart failure. Patients …

Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized …

S Bangalore, R Fakheri, B Toklu… - Mayo Clinic …, 2016 - mayoclinicproceedings.org
Objectives To compare the efficacy and safety of angiotensin-converting enzyme inhibitors
(ACEis) and angiotensin receptor blockers (ARBs) in patients without heart failure. Patients …

[引用][C] Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From …

S Bangalore, R Fakheri, B Toklu, G Ogedegbe… - Mayo Clinic …, 2016 - cir.nii.ac.jp
Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without
Heart Failure? Insights From 254,301 Patients From Randomized Trials | CiNii Research CiNii …

Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights from 254,301 Patients from Randomized Trials

S Bangalore, R Fakheri, B Toklu… - Mayo Clinic …, 2016 - nyuscholars.nyu.edu
Objectives To compare the efficacy and safety of angiotensin-converting enzyme inhibitors
(ACEis) and angiotensin receptor blockers (ARBs) in patients without heart failure. Patients …

Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized …

S Bangalore, R Fakheri, B Toklu, G Ogedegbe… - Mayo Clinic …, 2016 - sonar.ch
RESULTS Our search yielded 106 randomized trials that enrolled 254,301 patients.
Compared with placebo, ACEis but not ARBs reduced the outcomes of all-cause mortality …